MEDIA: Shelley Maclean
(613) 592-3400, ext. 2414 email@example.com
INVESTORS: Ana Raman
(613) 595-4580 firstname.lastname@example.org
For Immediate Release:
MDS Nordion Signs New Contract with Lantheus Medical Imaging, Inc.
for the Supply of Molybdenum-99
OTTAWA, CANADA – July 8, 2010 – MDS Nordion, a leading provider of products and services to the
global health science market, today announced it has signed a new contract with its primary customer, Lantheus
Medical Imaging, Inc. for the supply of Molybdenum-99 (Mo-99).
Mo-99, and, more specifically the derivative medial isotope Technetium-99m, is utilized in approximately 80
percent of nuclear medical procedures worldwide. These noninvasive procedures are essential for accurately
diagnosing and treating patients with conditions such as heart disease, cancer and neurological conditions.
“The continuous supply of medical isotopes to meet the needs of the global medical community and the patients it
serves has always been an important priority for Nordion. This contract with Lantheus further enables us to maintain
that commitment,” said Steve West, Chief Executive Officer, MDS Inc. “Our depth of expertise in the industry, world-
class logistical team and proven capability in the production of medical isotopes, provides Lantheus with a solid supply
Under the terms of the new agreement MDS Nordion will supply Mo-99 on a weekly basis to Lantheus Medical
Imaging, Inc. This contract is in place until July 31, 2011 and will commence once Atomic Energy of Canada Limited’s
(AECL) National Research Universal (NRU) reactor has returned to service which is anticipated to be the end of July,
“Lantheus and MDS Nordion have a long history of working together and this contract further demonstrates our
commitment to provide medical isotopes to the global nuclear medicine community,” said Don Kiepert, President
and Chief Executive O